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A B S T R A C T   
Myeloid derived suppressor cells (MDSCs) are a highly heterogeneous population of immature immune cells with 
immunosuppressive functions that are recruited to the tumor microenvironment (TME). MDSCs promote tumor 
growth and progression by inhibiting immune effector cell proliferation and function. MDSCs are affected by 
both novel anti-cancer therapies targeting the immune system to promote anti-tumor immunity, as well as by 
conventional treatments such as radiotherapy. Following radiotherapy, cytoplasmic double stranded DNA 
stimulates the cyclic GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING) pathway, resulting in 
type I interferon production. Effectiveness of radiotherapy and cGAS/STING signaling are closely intertwined: 
activation of cGAS and STING is key to generate systemic anti-tumor immunity after irradiation. This review 
focuses on how radiotherapy and cGAS/STING signaling in MDSCs and/or tumor cells impact MDSC recruitment, 
expansion and function. The influence of conventional and ablative radiotherapy treatment schedules, inflam-
matory response following radiotherapy, and hypoxia are discussed as MDSC modulators.   
1. Introduction MDSCs and the TME 
The tumor microenvironment (TME) is defined as the milieu sur-
rounding the tumor composed of vessels, soluble factors and multiple 
cell types, including immune cells and stromal cells such as pericytes 
and cancer associated fibroblasts [1,2]. Immune cells have gained great 
interest as targets in the development of anti-cancer therapies as specific 
immunotherapies have now been approved as treatment modality. New 
therapies that are being developed focus on immune regulatory path-
ways to enhance anti-tumor immunity, for instance by interference with 
immunosuppressive molecules and immune cells [3,4]. As a highly 
heterogeneous and immature myeloid population, myeloid derived 
suppressor cells (MDSCs) are part of the immunosuppressive 
populations present in the TME [5]. In a healthy state, MDSCs are almost 
undetectable in the blood [6]. However, especially in cancer, but also in 
other non-malignant pathological conditions such as chronic inflam-
mation, autoimmune diseases and infection, MDSC formation in the 
bone marrow is stimulated, reflected by elevated MDSC levels in the 
blood and subsequent recruitment to the pathological site [7–10]. MDSC 
expansion is driven by multiple different factors. In this process, specific 
cytokines and growth factors (such as tumor necrosis factor (TNF)α [11], 
granulocyte/macrophage colony-stimulating factor (GM-CSF) [12], 
vascular endothelial growth factor (VEGF) [13], interleukin (IL)-1β and 
indoleamine 2,3-dioxygenase (IDO), together with downstream medi-
ator IL-6 [14–16]) play an important role (reviewed in [17]). Moreover, 
the majority of solid tumors harbor areas with limited availability of 
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oxygen, favoring MDSC expansion [18]. At the pathological site, MDSCs 
suppress the function of effector cells such as T cells [9,19] and NK cells 
[20], skew macrophage polarization towards an immunosuppressive 
M2-like phenotype [21], and promote immunosuppressive Tregs 
[22,23]. 
1.1. MDSC subsets 
Broadly, two distinctive MDSC populations are defined, the mono-
cytic (M)-MDSCs (human CD11b+HLA-DR− /loCD14+CD15− ; murine 
equivalent CD11b+Gr1+Ly6G− Ly6Chi) and polymorphonuclear (PMN)- 
MDSCs (human CD11b+HLA-DR− /loCD14− CD15+; murine equivalent 
CD11b+Gr1+Ly6G+Ly6Clo) [24]. Additionally, a third population is 
described: early stage (e)-MDSCs (human Lin− HLA-DR− /loCD33+) de-
pict an even more immature progenitor of M-MDSCs and PMN-MDSCs 
[25]. Morphologically and phenotypically, MDSCs can hardly be 
distinguished from monocytes and neutrophils, although recently the 
lectin-type oxidized LDL receptor-1 (LOX-1) was suggested to be spe-
cifically expressed on PMN-MDSCs and not neutrophils [26,27]. Func-
tionally, however, MDSCs differ as they have immunosuppressive 
features and promote tumor progression [28–31]. As MDSCs are difficult 
to discriminate from other cells in blood, tissue or tumor samples, 
standardized methods to extract and phenotypically characterize this 
myeloid cell subset across different diseases are currently being evalu-
ated [8,32]. 
1.2. Immunosuppressive activities of MDSCs 
A key feature shared among MDSCs is their immunosuppressive 
character. Yet, specific MDSC subsets can operate in distinct manners. 
For example, M-MDSCs are associated with high levels of signal trans-
ducer and activator of transcription (STAT)1 and nitric oxide (NO) 
synthase [33], resulting in the generation of NO, which inhibits MHC 
class II expression [34] and influences T cell function by inducing T cell 
apoptosis [35]. On the other hand, PMN-MDSCs are much more asso-
ciated with high levels of ROS production induced by elevated levels of 
STAT3 [37] and NADPH oxidase activity [33], leading to suppression of 
T cells [36]. STAT1 and STAT3 are therefore important transcription 
regulators in M- and PMN-MDSCs [38–41]. Both MDSC populations 
have an elevated expression and activity of arginase, leading to deple-
tion of L-arginine and thereby impairing lymphocyte responses to anti-
gens by inhibiting T cell proliferation [42–44]. Another example of the 
immunosuppressive features of MDSCs is portrayed by the expression of 
inhibitory molecules such as programmed death (PD)-ligand 1 (PD-L1) 
[8,45] and a variety of Siglecs [4,5]. Moreover, M-MDSCs can rapidly 
differentiate into immunosuppressive M2-like tumor associated macro-
phages in the TME [46], a process which can be mediated by stromal 
cells in the TME [47]. In any case, MDSCs have multiple manners to 
suppress the TME, but most studies performed on MDSCs do not discern 
between MDSC subsets. For this reason, the exact role of the two main 
subsets remains to be further elucidated. 
1.3. Radiotherapy and the immune response 
It has become clear that long term efficacy of conventional anti- 
cancer therapies, such as chemotherapy and radiotherapy (RT), relies 
greatly on the recruitment and sustained presence of immune pop-
ulations in the tumor. Generally, chemotherapy and RT cause cell death 
of tumor cells by, amongst others, inducing excessive DNA damage [48]. 
However, several long-term anti-tumor effects of for instance chemo-
therapy are due to immune mediated responses [49]. Depending on 
tumor type and chemotherapeutic agent, MDSCs are distinctly affected 
[50–52]. RT was initially thought to be immunosuppressive rather than 
immunostimulatory, as immune cells, in particular lymphocytes, are 
known to be highly radiosensitive [53,54]. Nowadays, it is clear that RT 
can act as an ‘in situ vaccination’ strategy, resulting in an increased 
release of danger signals and tumor (neo-)antigens into the TME. Anti-
gen presenting cells (APCs) in the TME are able to engulf these antigens, 
present them to effector T cells, and initiate a systemic anti-tumor im-
mune response [55]. This so-called abscopal effect after irradiation 
limits progression of distant metastases outside the local irradiated area 
[56]. Inducing such anti-tumor immunity is highly dependent on RT 
dose and fractionation [57]. Additionally, RT may increase expression of 
PD-L1 on tumor- and immune cells, contributing to immunosuppression, 
and in part explaining the clinical success of the combination of RT with 
PD-1/PD-L1 immunotherapy [58,59]. Gaining insight in how RT in-
fluences immunosuppressive MDSCs could result in improved treatment 
outcomes. 
1.4. The cGAS/STING pathway 
One pathway entangled in boosting the anti-tumor immune response 
upon irradiation is the cyclic GMP-AMP (cGAMP) synthase (cGAS)/ 
stimulator of interferon genes (STING) pathway [60–63]. Both RT and 
chemotherapy are well known to induce DNA damage, accordingly 
leading to activation of the cGAS/STING pathway via sensing of double 
stranded DNA (dsDNA) fragments translocated to micronuclei or the 
cytoplasm (reviewed in [64]). cGAS binds to foreign or self-derived 
dsDNA, both nuclear and mitochondrial, and initiates a signaling 
cascade via second messenger 2′3′-cGAMP (referred to as cGAMP). Cy-
clic dinucleotides, such as cGAMP, serve as a ligand for STING, of which 
activation ultimately leads to the production of type I interferons (IFNs) 
in the TME [65,66]. Type I IFNs are potent immune cell activators, 
resulting in the activation and maturation of APCs [67,68]. Moreover, 
cGAS/STING signaling is crucial for the abscopal effect [69]. Intrigu-
ingly, in a case study of a melanoma patient, the rarely occurring 
abscopal response was observed concurrently with a decrease in MDSCs 
[70], suggesting a possible link between RT, cGAS/STING activation and 
MDSCs. Although the influence of RT and the cGAS/STING pathway in 
the TME is gradually being elucidated, how RT precisely affects MDSCs 
and whether cGAS/STING signaling is involved remains largely un-
known. In this review we will discuss recent publications exploring the 
impact of RT and cGAS/STING activation on MDSC regulation. 
2. Impact of radiotherapy on MDSCs 
It is becoming increasingly clear that RT and immunotherapy can 
synergize to induce systemic antitumor immune responses. Here we 
discuss the effect of radiation schedules, radiation induced inflammation 
and hypoxia on MDSCs upon RT treatment (Fig. 1). Therapeutic tar-
geting of MDSCs in the context of RT is further reviewed in [71] and 
[72]. 
2.1. Radiation schedules 
The type of radiation schedule is an important factor determining the 
effect of RT on MDSCs. The two main RT schedules are generally 
described as conventional fractionated radiation therapy (CFRT) or 
ablative hypofractionated radiation therapy (AHRT). CFRT schemes are 
composed of 20–30 daily low dose fractions (usually < 3 Gy). This 
fractionated RT schedule exploits the more efficient repair of DNA 
breaks of normal cells relative to tumor cells, resulting in less toxicity to 
the surrounding area, which allows to increase the number of fractions 
and thereby the total irradiation dose. Contrary, AHRT schemes rely on 
ablative irradiation doses (usually > 5 Gy). To prevent high levels of 
damage to the surrounding tissue, this treatment is executed by radio-
therapy equipment with on-board imaging, thereby limiting the volume 
of normal tissue being irradiated. Overall, AHRT comprises less fractions 
and a lower total dose of irradiation albeit at a higher dose per fraction. 
The larger fraction size (5–20 Gy) applied in ablative hypofractionated 
radiation therapy relative to smaller fractions (1.5–3 Gy) applied in 
conventional fractionated radiotherapy results in higher amounts of cell 
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damage and cell death, followed by the release of tumor antigens, cy-
tokines and other danger signals. Together, these factors contribute to 
immune cell infiltration and activation [73]. Intriguingly, it has been 
reported that CFRT and AHRT affect MDSCs in the TME differentially. 
CFRT schedules have shown to increase myeloid cell infiltration, 
including both intratumoral M-MDSCs and PMN-MDSCs, in an in vivo 
RM-1 prostate tumor mouse model after local irradiation [74]. In 
addition, total MDSC levels were elevated in tumor, spleen, lung, lymph 
node and peripheral blood. In this animal model, the CFRT schedule 
elicited the production of macrophage colony-stimulating factor (CSF1) 
[74], a growth factor playing an important role in inducing differenti-
ation, proliferation and migration of myeloid cells [75]. Concurrently 
with the increased levels of CSF1, both M-MDSC and PMN-MDSC 
accumulated in the tumor after RT. This effect diminished after 
blockade of the CSF1 receptor kinase signaling cascade, using a small- 
molecule kinase inhibitor. Further supporting CSF1 as MDSC- 
attracting factor in prostate cancer, data from prostate cancer patients 
revealed an increase in serum levels of CSF1 [74]. CSF1 could also 
contribute to immunosuppression by promoting the differentiation of 
MDSCs entering the TME into tumor associated macrophages [76]. Next 
to prostate cancer, cervical cancer patients present with heightened 
levels of circulating MDSCs upon CFRT, concurrent with reduced APC 
activity, further reinforcing the induction of MDSC recruitment upon 
CFRT [77]. By contrast, a 30 Gy ablative dose (AHRT) has been reported 
to reduce the recruitment of MDSCs in vivo in CT26 and MC38 murine 
colon carcinoma models [78]. In vivo studies comparing AHRT with 
CFRT schedules in Lewis lung carcinoma (LLC) and B16F10 melanoma 
murine models, demonstrate weakened recruitment of MDSCs in AHRT 
treated tumors [79]. The in vivo observed effect of AHRT on MDSC 
recruitment was ascribed to inhibition of the VEGF signaling pathway, 
vital for MDSC recruitment. Furthermore, in vivo studies show the po-
tential immune stimulatory effect of AHRT in mouse B16 melanoma and 
MC38/CT26 colon carcinoma models [55,80,81], also in comparison 
with CFRT [79]. However, whether CFRT or AHRT is conclusively su-
perior as a monotherapy in improving patient survival remains indeci-
sive [82–84]. This suggests other factors besides MDSCs recruitment and 
function determine patient survival, such as tumor type, tumor immu-
nogenicity or presence of other (immunosuppressive) immune cells. 
Evidently, the different RT schemes seem to affect MDSCs distinctly. 
CFRT is associated with an increased MDSC recruitment compared to 
AHRT. Given the immune-promoting environment induced by AHRT, it 
is conceivable fewer MDSCs are present in the TME, for instance due to a 
reduction in MDSC recruitment, or rapid differentiation of MDSC into 
neutrophils, macrophages or dendritic cells. All in all, the effect of RT on 
MDSCs could be important to consider in treatment decision making, 
especially when using immunotherapies targeting MDSCs. 
2.2. Inflammatory response 
A plethora of immunological factors are produced in the TME upon 
RT, among which a range of cytokines, leading to rapid infiltration of 
immune cells including MDSCs (reviewed in [85]). Of note, cytokine 
production following RT will vary in time and is also dependent on local 
conditions such as hypoxia. Even more, the type of radiation scheme (for 
instance CFRT vs AHRT) could shape the cytokine and chemokine pro-
file of the tumor [86]. Existing literature points towards the early in-
crease of many cytokines and growth factors upon RT, demonstrated by 
an upregulation of mRNA or protein levels. Established MDSC- 
Fig. 1. Model depicting the interplay between radiation schedule, hypoxia and MDSCs in shaping the TME. Various factors determine MDSC recruitment, function 
and maintenance in the TME. CFRT is associated with elevated MDSC levels in tumor and peripheral blood compared to AHRT, which is mediated by CSF1 and VEGF 
signaling. Additionally, MDSCs are preferably recruited to hypoxic environments via HIF-1α, VEGF and CCL26. Under hypoxic conditions, MDSCs are more 
immunosuppressive and produce higher levels of arginase and NO. Of note, this figure portrays various processes influencing MDSCs which do not necessarily occur 
simultaneously. After RT, levels of hypoxia may fluctuate depending on RT schedule and time after irradiation. Additionally, the predominant cytokines or proteins 
driving the MDSC response may differ depending on timing. AHRT: ablative hypofractionated radiotherapy; APC: antigen presenting cell; CCL26: chemokine (C–C 
motif) ligand; CFRT: conventional fractionated radiotherapy; CSF1: macrophage colony stimulating factor 1; HIF-1α: hypoxia inducible factor 1 subunit alpha; TME: 
tumor microenvironment; VEGF: vascular endothelial growth factor. 
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influencing factors such as TNFα rise after in vivo murine brain irradia-
tion [87], GM-CSF and IL-6 after in vitro irradiation of CHU-2 human 
squamous cell carcinoma cells [88], VEGF after in vitro irradiation of 
primary human glioblastoma cells [89], and type I IFNs after irradiation 
of human MCF-7 and T47D breast cancer cells in vitro [90] and mouse 
B16F10 melanoma and EL4 lymphoma cells in vivo [91]. Correspond-
ingly, an increase in the production of chemokines leads to the 
recruitment of different immune cells (reviewed in [86]), among them 
MDSCs. For example, a role for RT induced chemokine (C–C motif) 
ligand (CCL)2 in recruitment of MDSCs has previously been reported in 
several murine glioma models and pancreatic cancer patients [92–94]. 
Blockade of C–C chemokine receptor type 2 (CCR2), a chemokine re-
ceptor for CCL2 and to a lesser extent CCL7 and CCL12, enhanced the 
efficacy of RT on tumor regression in an MC38 colon carcinoma and LLC 
mouse model [95]. M-MDSCs were recruited to the tumor following RT, 
contributing to immunosuppression in the TME. These are a few ex-
amples of the potential of RT to affect MDSC recruitment. 
In addition to the boost in cytokine and growth factor production, 
the induction of the complement pathway is an important arm in the 
inflammatory response following RT [96]. Complement pathway acti-
vation leads to the production of various complement-components 
which induce inflammation. Complement factor C5 is assumed to be 
highly involved in the recruitment and regulation of MDSCs in the TME 
[97]. C5a, a cleaved product of C5, functions as a strong chemo-
attractant [98]. Tumor associated MDSCs express the C5a-receptor [99]. 
C5a stimulation in a TC-1 murine cervical cancer model results in an 
increase in integrin CD11b expression on PMN-MDSCs, presumably 
facilitating transfer over the endothelial barrier to reach the tumor. In 
addition, C5a stimulation enhances the ROS and NO formation by 
MDSCs, thereby increasing their suppressive capacity [99]. Vice versa, 
pharmacological blockade of C5a-receptor in LLC tumor-bearing mice 
reduced the total MDSC population in analyzed splenocytes, empha-
sizing the role of C5a in MDSC function [97]. 
2.3. Tumor hypoxia 
Next to the inflammatory state of a tumor, the oxygen consumption 
of tumors impacts the efficacy of RT. Rapid tumor growth combined 
with underdeveloped and unstructured vascularity often leads to an 
insufficient level of oxygen, a phenomenon called hypoxia, and is 
frequently observed in solid cancers. Irradiation-induced free radicals 
cause DNA damage, which can be repaired under hypoxia, whereas this 
DNA damage is fixed under normoxia (oxygen fixation hypothesis) 
[100]. For this reason, hypoxic tumors are much more resistant to RT 
[101]. Hypoxic cells, including MDSCs, produce different metabolites 
compared to cells under normoxia, affecting the TME [102,103]. For 
instance, mouse splenic MDSCs cultured under hypoxic conditions are 
more immunosuppressive compared to splenic MDSCs in normoxic 
levels and differentiate into macrophages [104]. This process is tightly 
linked to transcription factor hypoxia inducible factor 1 subunit alpha 
(HIF-1α). In an in vivo xenograft model using the human hepatocellular 
carcinoma cell line MHCC97L, HIF-1α has been shown to play an 
important role in the recruitment of MDSCs to hypoxic areas [105], in 
part via VEGF [13,106]. Next to HIF-1α, CCL26 has been described as an 
MDSC chemoattractant induced upon hypoxia [18]. MDSCs have an 
increased production of arginase and NO in hypoxic conditions, aug-
menting their immunosuppressive activity [104,107]. Finally, irradia-
tion alters the level of hypoxia, thereby influencing MDSCs [108]. For 
instance, LLC tumor-bearing mice receiving AHRT irradiation schemes 
present with lower levels of intratumoral hypoxia, possibly explaining 
the decrease in MDSCs [108]. On top of that, the expression of immu-
nosuppressive checkpoint molecule PD-L1 is regulated by HIF-1α and is 
greatly increased on many immune cells, including MDSCs, concurrent 
with a decreased percentage of CD4+IFNy+ and CD8+IFNy+ T cells in a 
murine LLC model [107]. Consequently, blocking of PD-L1 on MDSCs in 
a hypoxic environment alleviated MDSC mediated reduction of 
CD4+IFNy+ and CD8+IFNy+ T cells. Moreover, PD-L1 blocking on 
MDSCs in hypoxic environments reduced the production of IL-6 and IL- 
10. Interestingly, IL-10 was found to play an important part in the T cell 
suppressive function of MDSCs under hypoxia, in part explaining the 
increase of activated T cells following PD-L1 blocking of MDSCs [107]. 
Reducing hypoxia using an AHRT scheme rather than a CFRT scheme 
resulted in lower PD-L1 expression on MDSCs, possibly leading to an 
immunopermissive TME [79]. Importantly, the level of hypoxia is not 
only affected by irradiation, but also depends on fraction size and tumor 
characteristics, and may fluctuate during and after treatment. Alto-
gether, hypoxia is a major influencing factor regarding MDSCs. 
3. STING signaling and MDSCs 
It has become increasingly clear that MDSC recruitment and function 
is affected by RT. However, the impact of one of the key pathways 
activated after RT, the cGAS/STING pathway, on MDSCs has not been 
closely examined. The type I IFN signaling proteins induced by this 
pathway have a crucial role in immune cell function, including MDSCs. 
Triggering of the cGAS/STING pathway can occur intrinsically, within 
the MDSC, or MDSC-extrinsically in neighboring cells. Although cGAS is 
sparsely mentioned in context of MDSCs, several recent papers report 
that STING signaling may regulate MDSCs (Fig. 2). 
3.1. STING signaling suppresses MDSCs 
The majority of literature implies that STING signaling in the TME 
could suppress MDSC recruitment, differentiation and function. In B16 
melanoma tumor-bearing mice, intravenous administration of STING 
agonist cGAMP decreased the number of GR1+ and especially Ly6G+
PMN-MDSCs present in spleen and tumor [109]. Furthermore, MDSCs 
isolated from CT26 colon carcinoma tumor-bearing mice treated with 
intravenously injected cGAMP had a reduced T cell suppressive activity 
[109]. This is further illustrated in a model in which human nasopha-
ryngeal carcinoma (NPC) cells overexpressing STING were cocultured 
with CD33+ PBMCs in an MDSC differentiation assay [110]. In this 
assay, the percentage of MDSCs classified as HLA-DR− CD11b+CD33+, 
presumably e-MDSCs, was reduced when NPC cells overexpressed 
STING, indicating reduced MDSC expansion. Additionally, the capacity 
of MDSCs to inhibit T cell proliferation was diminished, implying loss of 
immunosuppressive features [110]. Mechanistically, there are various 
possible explanations for how STING signaling decreases MDSC func-
tion. In vitro, cGAMP treatment reduced NO and ROS production by 
splenic MDSCs isolated from B16 melanoma tumor-bearing mice, 
thereby reducing MDSC immunosuppressive function [109]. Moreover, 
independent of IFN-β production, STING overexpression in vitro in either 
NPC cells or MDSCs upregulated suppressor of cytokine signaling 1 
(SOCS1), a potent inhibitor of the Janus kinase (JAK)1/2 in the JAK/ 
STAT signaling pathway [110]. It was further established that SOCS1 
interacted directly with STAT3, thereby preventing STAT3 phosphory-
lation in NPC cells and MDSCs. As a result, the production and release of 
IL-6 and GM-CSF by NPC cells, two known drivers of MDSC expansion, 
was inhibited [110]. A recent paper suggests STAT3 inhibition could 
potentiate STING activation by cyclic dinucleotides in human monocytic 
leukemic THP1 cells [111]. These results imply that both MDSC-intrinsic 
and -extrinsic STING signaling could modulate MDSC function via 
STAT3. A recent publication by the same group proposes a means by 
which tumor cells and MDSCs can modulate STING signaling, namely 
via galectin-9 (Gal9) [112]. Gal9 is a protein that has a range of func-
tions and has been associated with immune escape of various cancer 
types [113], for instance via the induction of M2-macrophages. Forced 
overexpression of Gal9 in human NPC cell lines or MDSCs resulted in 
downregulation of STING by targeting the protein for proteasomal 
degradation [112]. Consequently, these MDSCs had an enhanced po-
tential to inhibit T cell proliferation, offering an interesting role for Gal9 
as a negative regulator of STING [112]. Overall, these studies enforce 
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the notion that STING signaling in both tumor cells and MDSCs coun-
teract MDSC expansion and suppressive activity, thereby contributing to 
an immune permissive TME. 
3.2. Reprogramming of MDSCs by STING 
Intriguingly, a recent study proposes MDSCs could be reprogrammed 
into immunostimulatory cells after MDSC-intrinsic STING activation 
[114]. MDSCs were examined in vivo in an LLC mouse model in context 
of PKR-like endoplasmic reticulum kinase (PERK), a protein involved in 
the unfolded protein response and a regulator of protein synthesis in 
case of ER stress. Tumor-infiltrating MDSCs contained large amounts of 
activated (phosphorylated) PERK and could strongly impair T cell pro-
liferation in mice. Deletion of PERK in the Lyz2 expressing myeloid 
subpopulation containing MDSCs delayed tumor growth in vivo and 
diminished the suppressive potential of MDSCs. Additionally, enhanced 
STING signaling could be detected in PERK-ablated MDSCs. This was 
mediated by downregulation of nuclear factor erythroid 2-related factor 
2 (NRF2) [114]. NRF2 is a protein playing a role in mitochondrial ho-
meostasis, by influencing the formation of ROS [115]. Downregulation 
of NRF2 in PERK-ablated MDSCs resulted in an increase in oxidative 
stress and release of mitochondrial DNA (mtDNA) [114]. Several results 
indicate that PERK-ablated MDSCs might become immunostimulatory. 
For instance, depletion of PERK-deficient MDSC-like cells using anti- 
GR1 or anti-CCL2 antibodies ensued in tumor progression rather than 
tumor control. Additionally, PERK-deficient tumor derived-MDSCs 
could more efficiently process and present antigens, and prime OT-I T 
cells compared to PERK-expressing tumor derived-MDSCs. STING is 
most likely responsible for this reprogramming of MDSCs, as the sup-
pressive potency of MDSCs was restored when STING was abolished in 
PERK-ablated MDSCs [114]. Altogether, these data uncover a mecha-
nism by which MDSC-intrinsic STING activation could reprogram 
immunosuppressive MDSCs to augment an anti-tumor immune 
response. Remarkably, transcription factor NRF2 has been implicated in 
MDSC survival and function before [116] as well as to radiation sensi-
tivity [117]. Compared to MDSCs isolated from 4T1 murine breast 
cancer tumor-bearing NRF2− /− mice, MDSCs from NRF2+/+ mice had an 
enhanced T cell suppressive activity by increasing secretion of ROS. 
Concurrently, presence of NRF2 alleviated oxidative stress in MDSCs, 
resulting in prolonged MDSC survival and tumor progression [116]. 
Deletion of NRF2 in mouse embryonic fibroblasts increased radiation 
sensitivity in vitro [117]. Whether MDSC-intrinsic STING activation 
contributed to the protective effect on tumor growth and survival in 
NRF2− /− mice remains to be determined. Altogether, MDSC-intrinsic 
Fig. 2. Schematic representation of putative MDSC-intrinsic and -extrinsic STING signaling in the TME. STING signaling could have profound effects on MDSC 
recruitment, expansion, maintenance and function. Activation of STING - demonstrated by STING phosphorylation - can be achieved in numerous ways. For instance, 
irradiation induced cytosolic dsDNA stimulates cGAS, followed by the production of STING ligand cGAMP. Release of mtDNA as a result of oxidative stress, mediated 
by ablation of PERK and/or NRF2, drives cGAS activation as well. Alternatively, exogenously delivered cGAMP or other STING ligands can activate STING in MDSCs 
or tumor cells. Moreover, cGAS- or cGAMP-independent STING activation is conceivable. Often the effect of STING signaling is mediated by IFN-β, but can also be 
independent of type I IFNs, for example by upregulation of SOCS1 which hampers STAT3 phosphorylation. Additionally, tumor cells and MDSCs may impede STING 
signaling by upregulating Gal9 or via other (unknown) mechanisms. MDSC-intrinsic and -extrinsic STING signaling negatively regulates MDSCs (green boxes) but 
could promote their recruitment as well (red box), contributing to tumor regression or progression, respectively. Importantly, timing and level of STING activation 
could contribute to these contradictory effects of STING signaling on MDSCs. CCL: chemokine (C–C motif) ligand; cGAMP: cyclic GMP-AMP; cGAS: cGAMP synthase; 
dsDNA: double stranded DNA; Gal9: galectin-9; IFN: interferon; NRF2: nuclear factor erythroid 2-related factor 2; PERK: protein kinase R-like endoplasmic reticulum 
kinase; SOCS1: suppressor of cytokine signaling 1; STAT3: signal transducer and activator of transcription 3; STING: stimulator of interferon genes. 
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STING activation could support the anti-tumor immune response by 
inhibiting and reprogramming MDSCs. 
3.3. STING dependent MDSC recruitment 
The majority of studies describe that both MDSC-intrinsic and 
-extrinsic STING signaling is associated with MDSC reduction, resulting 
in a favorable immune permissive TME composition. However, STING 
signaling has also been associated with MDSC recruitment [95]. Upon 
irradiation of tumors in vivo with a single fraction of 20 Gy or intra-
tumoral administration of STING agonist cGAMP, CCR2+ M-MDSCs 
were recruited to MC38 colon carcinoma and LLC tumors in a pre-
dominantly STING-dependent manner. IFN-β stimulated tumor cells to 
produce CCL2 and CCL7, illustrating how IFN-β production via STING 
could mobilize CCR2+ M-MDSCs to the tumor site, thereby contributing 
to immunosuppression [95]. Another publication reports decreased 
infiltration of M-MDSCs and PMN-MDSCs in tumor-draining lymph 
nodes of STING− /− mice bearing LLC tumors [118], suggesting STING 
signaling may be involved in MDSC recruitment. 
3.4. The effect of type I IFNs 
Although type I IFNs are effector molecules resulting from the cGAS/ 
STING signaling cascade, their effect on MDSCs is also described without 
taking cGAS/STING into consideration. Type I IFNs can be produced in 
various situations, for instance during viral infection [119]. IFN-α or 
IFN-β binds the IFN-α/β receptor (IFNAR), activating the JAK1-STAT1/2 
signaling cascade. This signaling pathway has been suggested to regu-
late PD-L1 expression on both M-MDSCs and PMN-MDSCs in murine 
AT3 breast cancer and CT26/MC38 colon carcinoma models [120]. In 
vitro stimulation of MDSCs with exogenous IFN-α/β decreased the fre-
quency of CD11b+GR1+ MDSCs; however, the remaining MDSCs pre-
sented with higher expression of PD-L1, dependent on IFNAR 
expression. JAK/STAT signaling inhibition could reduce the level of PD- 
L1 on both M-MDSCs and PMN-MDSCs, indicating involvement of the 
JAK/STAT pathway in PD-L1 regulation. High PD-L1 expressing MDSCs 
showed increased suppression of T cells, suggesting a more efficient 
overall immunosuppression. MDSCs themselves also produced type I 
IFNs, implying an autocrine manner to increase or sustain their immu-
nosuppressive features [120]. Next to the JAK/STAT pathway, type I IFN 
secretion via IRF7 is proposed to affect MDSC mobilization in an in vivo 
4T1 mouse breast cancer model [121]. In this model, type I IFN signaling 
leads to an IRF7 dependent tumor cell dormancy by suppressing MDSCs 
mobilization and promoting intratumoral CD4+ and CD8+ T cell accu-
mulation. These findings were reinforced by showing that an absence of 
IFN-β in breast cancer patients’ sera after chemotherapy correlated with 
shorter metastasis free survival, implying the necessity of type I IFN 
signaling and suppression of MDSC mobilization to acquire tumor 
dormancy [121]. All in all, these data show the importance of type I IFN 
signaling on MDSCs. 
4. Future perspectives and concluding remarks 
The above discussed literature describes an intricate role of RT and 
cGAS/STING signaling in regulating MDSCs and opens up new questions 
on how RT and cGAS/STING activation could be exploited to target and 
reprogram MDSCs to increase tumor control and survival (Open ques-
tions box). Radiation dose and schedule, induction of an overall in-
flammatory response and the presence of hypoxia are notable factors 
when studying MDSCs in the context of RT. In addition, cGAS/STING 
signaling is inevitable in RT research. STING signaling after RT could 
enhance immunosuppression in the TME by recruiting CCR2+ M-MDSCs 
via secretion of IFN-β. By contrast, expression and activation of STING in 
both tumor cells and MDSCs diminished the suppressive potential and 
might even help to reprogram MDSCs into immunostimulatory cells.  
Peculiarly, STING its upstream signaling partner cGAS is sparsely 
mentioned and investigated in current literature on MDSCs, despite the 
obvious role of cGAS in STING signaling caused by RT [95] and/or 
mtDNA [114]. With regards to MDSC regulation, what remains unclear 
is whether STING is unique in possessing a regulatory potential or 
whether the secreted IFN-β is the ‘culprit’. Undoubtedly, type I IFNs are 
vital in generating an effective anti-tumor immune response, and often 
STING is identified as the main driver. Still, other signaling pathways 
culminate in type I IFN production, questioning whether STING 
signaling could be replaced by another type I IFN producing pathway. 
Although STING signaling is merely portrayed as an instruction to the 
cell to produce type I IFNs, it is important to recognize that STING has 
other functions as well, for instance in autophagy [122] and inflam-
masome initiation [123]. In case of MDSC regulation, SOCS1 expression 
was regulated by STING independent of type I IFNs [110]. Nevertheless, 
STING remains the central mediator of type I IFN production after 
irradiation, as cGAS mediated cGAMP production following cytoplasmic 
dsDNA recognition provides a potent stimulus activating STING. Be-
sides, STING is relatively easy to therapeutically target considering the 
broad availability of STING agonists. The question arises whether such a 
therapy should be directed towards STING signaling in tumor cells 
(MDSC-extrinsic) or in MDSCs(-intrinsic), or both. As illustrated by 
Mohamed et al. [114], reprogramming of immunosuppressive MDSCs 
occurs when endogenous STING is activated, whereas Zhang and col-
leagues [110] argue either MDSC-intrinsic or -extrinsic STING signaling 
is sufficient to affect MDSC expansion and function. So far, it remains 
elusive in which cells STING has the biggest impact on reversing the 
immunosuppressive TME. 
Although limited papers are published on cGAS/STING signaling in 
MDSCs, the major importance of this signaling pathway is becoming 
increasingly clear. Further investigation of this pathway in MDSCs could 
help to decipher the optimal (RT) conditions to counteract these 
immunosuppressive cells. Moreover, elucidating the complex role of 
cGAS/STING in MDSC reprogramming could ultimately lead to new 
strategies to create a TME with increased sensitivity to immunotherapy 
of cancer. 
Open questions box   
- How important is STING activation in regulating MDSCs? Is STING redundant: could other type I IFN producing pathways replace the cGAS/ 
STING pathway? Is STING solely involved in MDSC regulation due to production of type I IFNs? What are functions of STING independent of 
type I IFN production that could regulate MDSCs?  
- Does MDSC-intrinsic or -extrinsic STING activation have the greatest impact on MDSCs, or are both equally involved? Therapy-wise, should 
MDSC-intrinsic STING, -extrinsic STING or both be targeted to promote tumor control and improve patient survival?  
- How is cGAS involved in MDSC regulation via STING? What RT schedules are optimal to counteract MDSC suppressiveness?  
- How can we optimally reprogram MDSCs into immunostimulatory APCs using cGAS/STING activation? Could RT promote reprogramming of 
MDSCs by stimulating cGAS/STING?  
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